Bonum Therapeutics to Present Posters and a Short Talk on its Novel Platform for Generating Conditionally Activated Targeted Therapies at Keystone Conference
April 29, 2024
“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”
- John Mulligan, Founder and CEO, Bonum Therapeutics
Bonum Therapeutics to Present Lead Program at AACR
“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”
March 5, 2024
Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies
“We believe that this technology has broad potential and we are excited to apply it in new areas…”
Nov 15, 2022
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche
“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”